Clinical Trial Detail

NCT ID NCT03153982
Title Ruxolitinib in Operable Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

head and neck squamous cell carcinoma

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.